GLP-1 Drug Pricing Guide: Best Prices as of April 2026
Complete guide to GLP-1 drug prices in April 2026 covering Ozempic, Wegovy, Mounjaro, Zepbound, Foundayo, compounded options, India generics, and government programs.
The GLP-1 pricing landscape has fragmented dramatically in 2026. The same drug — semaglutide — now ranges from $14/month (Indian generic) to $1,349/month (US list price), a 96x spread. Between TrumpRx deals, manufacturer direct programs, new subscription models, and India's post-patent generic flood, the sticker price has become increasingly disconnected from what patients actually pay.
The bottom line for patients: If you have commercial insurance with GLP-1 coverage, you'll pay as little as $25/month with a manufacturer savings card — regardless of which drug you choose. If you're uninsured, the cheapest entry points are Foundayo at $149/mo (LillyDirect) and Ozempic at $199/mo (NovoCare intro offer). For long-term uninsured maintenance, Wegovy's 12-month subscription at $249/mo is the best deal. Medicare patients pay $50/mo through the TrumpRx program.
Below is a comprehensive breakdown of every major GLP-1 medication, what you'll actually pay through each channel, and where the market is headed. All prices are current as of April 2026 and cited to primary sources. For a visual overview of how prices have changed over time, see our GLP-1 Pricing Trends charts.
Key context: Nobody pays list price anymore. The WAC (Wholesale Acquisition Cost) figures listed below exist primarily for insurance reimbursement calculations and rebate negotiations. What matters is the self-pay, TrumpRx, and insurance copay prices — those are what patients actually see at checkout. Novo Nordisk has announced WAC cuts to ~$675/mo effective January 2027, which will finally bring list prices closer to reality.
Ozempic (Semaglutide Injection, for Diabetes)
Novo Nordisk's injectable semaglutide for type 2 diabetes. Available in 0.25 mg, 0.5 mg, 1 mg, and 2 mg doses. Currently covered by most commercial insurance and Medicare Part D for diabetes.
| Channel | Price | Source |
|---|---|---|
| List Price (WAC) | $1,027/mo | NovoCare |
| NovoCare Self-Pay | $349/mo | Novo Nordisk PR |
| New Patient Intro Offer | $199/mo | Novo Nordisk PR |
| TrumpRx / Medicare | $245/mo | AJMC |
| Commercial Insurance + Savings Card | As low as $25/mo | NovoCare |
| 2027 List Price (Announced) | $675/mo | Novo Nordisk PR |
Wegovy (Semaglutide Injection, for Obesity)
Novo Nordisk's injectable semaglutide for chronic weight management. Available in escalating doses from 0.25 mg to 2.4 mg. In March 2026, Novo launched a first-of-its-kind multi-month subscription program.
| Channel | Price | Source |
|---|---|---|
| List Price (WAC) | $1,349/mo | NovoCare |
| NovoCare Self-Pay | $499/mo | Novo Nordisk PR |
| 12-Month Subscription | $249/mo | Novo Nordisk PR |
| 6-Month Subscription | $299/mo | Novo Nordisk PR |
| 3-Month Subscription | $329/mo | Novo Nordisk PR |
| TrumpRx / Medicare | $245/mo | Pharmacy Times |
| Commercial Insurance + Savings Card | As low as $25/mo | Wegovy.com |
| 2027 List Price (Announced) | $675/mo | Novo Nordisk PR |
Wegovy Pill (Oral Semaglutide 25 mg, for Obesity)
Novo Nordisk's oral semaglutide tablet for weight management, FDA-approved December 2025. Must be taken on an empty stomach with water, followed by a 30-minute wait before eating. Doses escalate from 1.5 mg to 25 mg.
| Channel | Price | Source |
|---|---|---|
| List Price (WAC) | $1,349/mo | NovoCare |
| Self-Pay (Starter Doses) | $149/mo | NovoCare Price Guide |
| Self-Pay (Maintenance Doses) | $299/mo | NovoCare Price Guide |
| TrumpRx (Oral GLP-1) | $150/mo | AMCP |
Mounjaro (Tirzepatide Injection, for Diabetes)
Eli Lilly's dual GLP-1/GIP agonist for type 2 diabetes. Available in doses from 2.5 mg to 15 mg. Lilly introduced single-dose vials at lower price points via LillyDirect.
| Channel | Price | Source |
|---|---|---|
| List Price (WAC) | $1,080/mo | Lilly Pricing Info |
| LillyDirect Vials (Starting Dose) | $299/mo | FindHonestCare |
| LillyDirect Vials (Mid Dose) | $399/mo | FindHonestCare |
| LillyDirect Vials (Higher Doses) | $449/mo | FindHonestCare |
| TrumpRx / Medicare | $245/mo | Eli Lilly IR |
| Commercial Insurance + Savings Card | As low as $25/mo | Lilly Pricing Info |
Zepbound (Tirzepatide Injection, for Obesity)
Eli Lilly's tirzepatide for chronic weight management. Same molecule as Mounjaro but approved for obesity. Available through LillyDirect at significantly reduced self-pay prices.
| Channel | Price | Source |
|---|---|---|
| List Price (WAC) | $1,086/mo | Lilly Pricing Info |
| LillyDirect Vials (Starting Dose) | $299/mo | Eli Lilly IR |
| LillyDirect Vials (Mid Dose) | $399/mo | Eli Lilly IR |
| LillyDirect Vials (Higher Doses) | $449/mo | Eli Lilly IR |
| TrumpRx | $346/mo | AJMC |
| Medicare | $245/mo | Eli Lilly IR |
| Commercial Insurance + Savings Card | As low as $25/mo | Zepbound.com |
Foundayo (Orforglipron, Oral GLP-1 Pill for Obesity)
Eli Lilly's newly launched oral GLP-1 pill, FDA-approved April 1, 2026 and available since April 9. The only GLP-1 pill with no food or water restrictions — can be taken any time of day. Doses range from 0.8 mg to 17.2 mg.
| Channel | Price | Source |
|---|---|---|
| List Price (WAC) | $649/mo | GoodRx |
| LillyDirect (Starting Dose) | $149/mo | Eli Lilly PR |
| LillyDirect (Most Patients) | ~$349/mo | Drugs.com |
| TrumpRx (Oral GLP-1) | $150/mo | AMCP |
| Medicare Part D | $50/mo copay | Eli Lilly PR |
| Commercial Insurance + Savings Card | As low as $25/mo | Eli Lilly PR |
Compounded Semaglutide & Tirzepatide
Compounded versions remain available through 503A pharmacies and some 503B outsourcing facilities despite ongoing FDA enforcement. Supply has tightened and low-end prices have risen since the 2024-2025 era. Semaglutide was removed from the FDA drug shortage list in February 2025.
| Channel | Price | Source |
|---|---|---|
| Compounded Semaglutide (Starting Dose) | $159–$199/mo | Newswire / Trinity Meds |
| Compounded Semaglutide (Higher Doses) | $299–$499/mo | Newswire / Trinity Meds |
| Compounded Tirzepatide | $229–$349/mo | HealthFactsJournal |
| Pre-Crackdown Pricing (2024) | $150–$400/mo | ArentFox Schiff |
India Generic Semaglutide (Post Patent Expiry)
Semaglutide's Indian patent expired March 20, 2026, triggering an immediate flood of 26+ branded generics from 13 companies. Prices dropped up to 90% from branded levels. These generics are only available in India — US patents extend into the 2030s.
| Channel | Price | Source |
|---|---|---|
| Cheapest Generics (Natco, Glenmark) | $15–$21/mo | NirvanaClinics |
| Mid-Range Generics (Alkem, Zydus) | $21–$26/mo | NirvanaClinics |
| Premium Generics (Sun Pharma, Dr. Reddy's) | $36–$50/mo | Business Today India |
| Branded Ozempic (India, Post-Cut) | $67–$133/mo | Business Standard |
TrumpRx Program & Medicare Coverage
The Trump administration launched TrumpRx.gov in February 2026 as a centralized portal for discounted GLP-1 access. Both Lilly and Novo Nordisk agreed to Most-Favored-Nation (MFN) pricing. Medicare obesity coverage launches through a bridge program in July 2026.
| Channel | Price | Source |
|---|---|---|
| Injectable GLP-1s (TrumpRx Self-Pay) | $350/mo | AJMC |
| Oral GLP-1s (TrumpRx Self-Pay) | $150/mo | AMCP |
| Medicare (All GLP-1s) | $245/mo | Pharmacy Times |
| Medicare Patient Copay | $50/mo | SavingAdvice |
| Medicare Obesity Bridge (Launches July 2026) | $50/mo copay | KFF |